Marfan syndrome: Progress report

Progress in Pediatric Cardiology

Volumn 34, Issue 1, 2012, Pages 9-14

  Franken, Romy ^a,b   den Hartog, Alexander W ^a,b   Singh, Michael ^c   Pals, Gerard ^d   Zwinderman, Aeilko H ^a   Groenink, Maarten ^a,b   Mulder, Barbara J M ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aortic root dilatation; Clinical implications; Ghent criteria; Losartan therapy; Marfan syndrome; Revised Ghent criteria

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FIBRILLIN 1; LOSARTAN; NEBIVOLOL; PLACEBO;

ARTICLE; BODY SURFACE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; GENE MUTATION; GENETIC SCREENING; HEART SURGERY; HUMAN; MARFAN SYNDROME; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT INDICATION;

EID: 84864987684     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2012.05.003     Document Type: Article

References (54)

1. Judge DP, Dietz HC Marfan's syndrome. Lancet 2005, 366(9501):1965-1976.
2. Groenink M, Lohuis TA, Tijssen JG, et al. Survival and complication free survival in Marfan's syndrome: implications of current guidelines. Heart 1999, 82(4):499-504.
3. Groenink M, de Roos A, Mulder BJ Biophysical properties of the normal-sized aorta in patients with Marfan syndrome: evaluation with MR flow mapping. Radiology 2001, 219(2):535-540.
4. Jeremy RW, Huang H, Hwa J, et al. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome. Am J Cardiol 1994, 74(4):369-373.
5. Nollen GJ, Groenink M, van der Wall EE, Mulder BJ Current insights in diagnosis and management of the cardiovascular complications of Marfan's syndrome. Cardiol Young 2002, 12(4):320-327.
6. Nollen GJ, Mulder BJ What is new in the Marfan syndrome?. Int J Cardiol 2004, 97(Suppl. 1):103-108.
7. Oosterhof T, Groenink M, Hulsmans FJ, et al. Quantitative assessment of dural ectasia as a marker for Marfan syndrome. Radiology 2001, 220(2):514-518.
8. Zadeh N, Bernstein JA, Niemi AK, et al. Ectopia lentis as the presenting and primary feature in Marfan syndrome. Am J Med Genet A 2011, 155A(11):2661-2668.
9. Faivre L, Collod-Beroud G, Loeys BL, et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am J Hum Genet 2007, 81(3):454-466.
10. Groenink M, Rozendaal L, Naeff MS, et al. Marfan syndrome in children and adolescents: predictive and prognostic value of aortic root growth for screening for aortic complications. Heart 1998, 80(2):163-169.
11. Milewicz DM, Dietz HC, Miller DC Treatment of aortic disease in patients with Marfan syndrome. Circulation 2005, 111(11):e150-e157.
12. Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA Life expectancy and causes of death in the Marfan syndrome. N Engl J Med 1972, 286(15):804-808.
13. De Paepe A, Devereux RB, Dietz HC, Hennekam RC, Pyeritz RE Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996, 62(4):417-426.
14. Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan syndrome. J Med Genet 2010, 47(7):476-485.
15. Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J Cardiol 1995, 75(2):157-160.
16. Shores J, Berger KR, Murphy EA, Pyeritz RE Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med 1994, 330(19):1335-1341.
17. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991, 352(6333):337-339.
18. Ramirez F, Rifkin DB Cell signaling events: a view from the matrix. Matrix Biol 2003, 22(2):101-107.
19. ten Dijke P, Hill CS New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004, 29(5):265-273.
20. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312(5770):117-121.
21. Marfan AB Un cas de déformation congénitale des quarte membres, plus prononcée aux extrémités caracterisée par l'allongement des os avec un certain degré d'amincissement. Bull Mem Soc Med Hop Paris 1896, 13:220-226.
22. McKusick VA The cardiovascular aspects of Marfan's syndrome: a heritable disorder of connective tissue. Circulation 1955, 11(3):321-342.
23. Beighton P, De Paepe A, Danks D, et al. International nosology of heritable disorders of connective tissue, Berlin, 1986. Am J Med Genet 1988, 29(3):581-594.
24. Dietz HC, Pyeritz RE, Puffenberger EG, et al. Marfan phenotype variability in a family segregating a missense mutation in the epidermal growth factor-like motif of the fibrillin gene. J Clin Invest 1992, 89(5):1674-1680.
25. Stheneur C, Collod-Beroud G, Faivre L, et al. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet 2009, 17(9):1121-1128.
26. Faivre L, Masurel-Paulet A, Collod-Beroud G, et al. Clinical and molecular study of 320 children with Marfan syndrome and related type I fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics 2009, 123(1):391-398.
27. Aalberts JJ, Schuurman AG, Pals G, et al. Recurrent and founder mutations in the Netherlands: extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation. Neth Heart J 2010, 18(2):85-89.
28. Radonic T, de Witte P Groenink M et al 2011, Critical appraisal of the revised Ghent criteria for diagnosis of Marfan syndrome, Clin Genet.
29. Faivre L, Collod-Beroud G, Ades L The new Ghent criteria for Marfan syndrome: what do they change?. Clin Genet 2011.
30. Roman MJ, Devereux RB, Kramer-Fox R, O'Loughlin J Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol 1989, 64(8):507-512.
31. Kinoshita N, Mimura J, Obayashi C, et al. Aortic root dilatation among young competitive athletes: echocardiographic screening of 1929 athletes between 15 and 34 years of age. Am Heart J 2000, 139(4):723-728.
32. Reed CM, Richey PA, Pulliam DA, Somes GW, Alpert BS Aortic dimensions in tall men and women. Am J Cardiol 1993, 71(7):608-610.
33. Pelliccia A, Di Paolo FM, De Blasiis E Prevalence and clinical significance of aortic root dilation in highly trained competitive athletes. Circulation 2010, 122(7):698-706. 3.
34. Rozendaal L, Groenink M, Naeff MS, et al. Marfan syndrome in children and adolescents: an adjusted nomogram for screening aortic root dilatation. Heart 1998, 79(1):69-72.
35. Van Engelen K, Mulder BJM Connective tissue disorders and smooth muscle disorders in cardiology. Clinical cardiogenetics 2011, 267-268. Springer, London. 1 ed. H.F. Baars, J.J. Van Der Smagt, P.A.F.M. Doevendans (Eds.).
36. Oosterhof T, Nollen GJ, van der Wall EE, et al. Comparison of aortic stiffness in patients with juvenile forms of ascending aortic dilatation with versus without Marfan's syndrome. Am J Cardiol 2005, 95(8):996-998.
37. Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med 1999, 340(17):1307-1313.
38. Meijboom LJ, Timmermans J, Zwinderman AH, Engelfriet PM, Mulder BJ Aortic root growth in men and women with the Marfan's syndrome. Am J Cardiol 2005, 96(10):1441-1444.
39. Roman MJ, Rosen SE, Kramer-Fox R, Devereux RB Prognostic significance of the pattern of aortic root dilation in the Marfan syndrome. J Am Coll Cardiol 1993, 22(5):1470-1476.
40. Nollen GJ, Groenink M, Tijssen JG, van der Wall EE, Mulder BJ Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. Eur Heart J 2004, 25(13):1146-1152.
41. van Karnebeek CD, Naeff MS, Mulder BJ, Hennekam RC, Offringa M Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 2001, 84(2):129-137.
42. Boucek RJ, Noble NL, Gunja-Smith Z, Butler WT The Marfan syndrome: a deficiency in chemically stable collagen cross-links. N Engl J Med 1981, 305(17):988-991.
43. Boucek RJ, Gunja-Smith Z, Noble NL, Simpson CF Modulation by propranolol of the lysyl cross-links in aortic elastin and collagen of the aneurysm-prone turkey. Biochem Pharmacol 1983, 32(2):275-280.
44. Carlson RG, Lillehei CW, Edwards JE Cystic medial necrosis of the ascending aorta in relation to age and hypertension. Am J Cardiol 1970, 25(4):411-415.
45. Nagashima H, Sakomura Y, Aoka Y, et al. Angiotensin II type 2 receptor mediates vascular smooth muscle cell apoptosis in cystic medial degeneration associated with Marfan's syndrome. Circulation 2001, 104(12 Suppl 1):I282-I287.
46. Neptune ER, Frischmeyer PA, Arking DE, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33(3):407-411.
47. Ng CM, Cheng A, Myers LA, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004, 114(11):1586-1592.
48. Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005, 112(17):2668-2676.
49. Pueyo ME, Michel JB Angiotensin II receptors in endothelial cells. Gen Pharmacol 1997, 29(5):691-696.
50. Rueckschloss U, Quinn MT, Holtz J, Morawietz H Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002, 22(11):1845-1851.
51. Habashi JP, Doyle JJ, Holm TM, et al. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism. Science 2011, 332(6027):361-365.
52. Jones ES, Black MJ, Widdop RE Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol 2004, 37(5):1023-1030.
53. Arslan-Kirchner M, Arbustini E, Boileau C Clinical utility gene card for: Marfan syndrome type 1 and related phenotypes [FBN1]. Eur J Hum Genet 2010, 18(9).
54. Brooke BS, Habashi JP, Judge DP, et al. Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med 2008, 358(26):2787-2795.